Pages that link to "Q34152580"
Jump to navigation
Jump to search
The following pages link to Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67 (Q34152580):
Displaying 32 items.
- Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries (Q26748763) (← links)
- Determinants of orphan drugs prices in France: a regression analysis (Q33587572) (← links)
- Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe (Q33604678) (← links)
- Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease (Q33684105) (← links)
- Pricing and reimbursement of orphan drugs: the need for more transparency (Q34193502) (← links)
- Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation (Q35835153) (← links)
- Choosing vs. allocating: discrete choice experiments and constant-sum paired comparisons for the elicitation of societal preferences (Q37333597) (← links)
- Orphan Drug Pricing: An Original Exponential Model Relating Price to the Number of Patients (Q37542316) (← links)
- Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL). (Q37692633) (← links)
- Rare lung disease and orphan drug development (Q38178791) (← links)
- Orphan drugs policies: a suitable case for treatment (Q38179281) (← links)
- SCIENTIFIC AND SOCIAL VALUE JUDGMENTS FOR ORPHAN DRUGS IN HEALTH TECHNOLOGY ASSESSMENT. (Q38821595) (← links)
- A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact? (Q38994340) (← links)
- General knowledge and opinion of future health care and non-health care professionals on rare diseases (Q39104523) (← links)
- Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain (Q39555796) (← links)
- What is known about the cost-effectiveness of orphan drugs? Evidence from cost-utility analyses (Q41043413) (← links)
- Challenges in measuring the societal value of orphan drugs: insights from a canadian stated preference survey. (Q41585720) (← links)
- Cost-effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus (Q42636265) (← links)
- Eliciting preferences for prioritizing treatment of rare diseases: the role of opportunity costs and framing effects (Q44347605) (← links)
- Orphan drugs for rare diseases: is it time to revisit their special market access status? (Q44871497) (← links)
- Attitudes toward supplementary criteria in the reimbursement process in Poland (Q45372407) (← links)
- Communal Sharing and the Provision of Low-Volume High-Cost Health Services: Results of a Survey (Q46313513) (← links)
- Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease (Q47121756) (← links)
- Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders (Q47571494) (← links)
- Real life cost and quality of life associated with continuous intraduodenal levodopa infusion compared with oral treatment in Parkinson patients (Q48064134) (← links)
- Constant-sum paired comparisons for eliciting stated preferences: a tutorial (Q48070495) (← links)
- Rare disease prevention and treatment: the need for a level playing field (Q50071892) (← links)
- Prioritizing Rare Diseases: Psychological Effects Influencing Medical Decision Making (Q51005093) (← links)
- The Need for Transparency and Efficiency in Reimbursement Decisions Relating to Drugs for Rare Diseases (Q58056225) (← links)
- Patient access to orphan drugs in France (Q64040473) (← links)
- Mapping of Current Obstacles for Rationalizing Use of Medicines (CORUM) in Europe: Current Situation and Potential Solutions (Q90478640) (← links)
- Moving Towards Accountability for Reasonableness - A Systematic Exploration of the Features of Legitimate Healthcare Coverage Decision-Making Processes Using Rare Diseases and Regenerative Therapies as a Case Study (Q92807900) (← links)